Advertisement
Advertisement
TOPIC

China’s private sector

China’s private sector
The latest news, analysis and opinion on China’s private sector. In-depth analysis, industry insights and expert opinion.
The cost advantages of Chinese pharmaceuticals mean they still appeal to multinational drug makers despite US security concerns. Photo: TNS
Biomedicine: Companies

Chinese pharmaceutical firms’ cost advantages trump Pentagon blacklist: analysts

Growing collaboration between multinational drug makers and Chinese companies not expected to slow after US move.

Microsoft

Microsoft cuts hundreds of mainland cloud jobs, as China, US tighten data laws

United States

China market is the ‘world’s toughest gym’ for global brands: McKinsey

8
Biomedicine: Companies

Which company could become the Chinese Pfizer? Here are analysts’ top picks

A boom in outlicensing agreements leads to a debate over which Chinese firms may be first to break into overseas markets with own brands.

Chinese pharmaceutical companies may expand into international markets in the coming years. Photo: Shutterstock
Biomedicine: Companies

With AI able to predict disease, can we treat ageing like a ‘bug’ in the system?

AI is transforming longevity as companies like METiS TechBio and Human Longevity use algorithms to combat ageing and predict health risks.

Mainland China

The big scoop: lemon tea chain to revamp Haagen-Dazs’ struggling China business

General Mills is offloading the ice cream brand’s mainland China stores, as foreign businesses revamp models amid heated domestic competition.

videocam
Advertisement
Advertisement
Advertisement
Biomedicine: Companies

Akeso lung cancer drug trial raises hopes in US$20b market

Ivonescimab phase three trials reduce death risk by 34 per cent, as analysts predict it could transform non-small cell lung cancer therapy.

Illustration of a healthy lung and a smoker's lung. Photo: Shutterstock
Biomedicine: Companies

China’s biotech boom drives surge in home-grown innovative drug approvals

Domestic firms dominate China’s drug approvals amid jump in spending and out-licensing deals as regulator speeds path to market.

Biomedicine: Companies

Insilico, US partner to build AI models predicting disease decades ahead

Tie-up combines Hong Kong-listed Insilico Medicine’s algorithms with Human Longevity’s genomic data to advance personalised health research.

Guangzhou

A new battlefront for KFC and its Chinese rivals: the lighter meal

Big-name fast-food chains are seeking to capitalise on a surge in demand in China for lighter meals.

A drink and several meals from KPRO’s menu. Photo: Handout
Mainland China

Baidu says AI now primary business driver despite 2% drop in first-quarter revenue

Analysts expect the company’s AI marketing services base to steadily grow to reduce declines in advertising revenue and boost profits.

videocam
The Baidu logo is displayed at the company building in Shenzhen. Photo: Getty Images
China stock market

‘Explosive’: why China’s gold recycling industry is growing at record speed

More than half of the country’s gold recycling firms are less than three years old.

Banking & finance

China’s credit demand weak in April despite policy support, strong industry

Lending growth slows as borrowing demand from households and businesses remains weak.

China-EU relations

German firms in China more optimistic despite Iran war, trade headwinds: survey

Expectations for growth, profits and investment are all up, despite geopolitical turbulence.

German and Chinese national flags flutter on a lamppost at Tiananmen Gate in Beijing. Photo: Shutterstock
Biomedicine: Companies

China’s Hengrui seals US$15.2 billion deal with US pharmaceutical giant BMS

Company’s shares jump in Hong Kong and Shenzhen after tie-up that bolsters China’s growing drug innovation profile.

A worker checks a feeding tray at the Hengrui Biomedical Industrial Park in Lianyungang, east China’s Jiangsu province. Photo: Getty Images
Stocks

After accounting overhaul, can Wuliangye share buys restore investor confidence?

Investors welcome Wuliangye’s multibillion-yuan share purchase plan after weak earnings and industry destocking hit sentiment.

Artificial intelligence

Kimi developer Moonshot AI valued at US$20b as it navigates new IPO rules

Firm raised US$2 billion from investors including Meituan’s venture and China Mobile, taking total to US$3.9 billion in the last six months.

Advertisement
Advertisement
Advertisement
Britain

CK Hutchison exits UK’s largest carrier VodafoneThree in US$5.82 billion deal

Sale of 49 per cent stake marks CK Hutchison’s latest asset move, following disposal of UK Power Networks, as group builds cash war chest.

videocam
Hong Kong-listed conglomerate CK Hutchison has agreed to exit its 49 per cent stake in the UK’s largest mobile operator VodafoneThree. Photo: CK Hutchison
Mainland China

WuXi AppTec posts record first-quarter revenue on strong global demand

Earnings top estimates as multinational pharmaceutical firms ramp up investment and partnerships in China.

Mainland China

Turning cast-offs into cash: China’s Zhuanzhuan looks to Europe, US for growth

From phones to luxury bags, the recycling platform wants to take its ‘trash to treasure’ model global as second-hand demand accelerates.

Indonesia

Muddy yet clear-cut: how Chinese investors are turning jungle into a new capital

Chinese construction firms keen to cement trade ties with Jakarta through multimillion dollar projects to build a brand new centre of power.

videocam
Construction started on a Chinese-invested commercial centre at Ibu Kota Nusantara, the future Indonesian capital, on September 22, 2025. Photo: Ralph Jennings
Biomedicine: Companies

How China’s ‘landmark’ drug pricing guidelines could be a boon for biotech

State Council calls for ‘value-based pricing’ for innovative drugs, a move researchers said would benefit private healthcare players.

Chinese biotech firms reached 157 agreements to out-licence early-stage drugs last year. Photo: Shutterstock
Biomedicine: Companies

Chinese drug makers take on Western dominance in US$16 billion Parkinson’s race

The future of treating brain diseases could lie in non-invasive technologies, according to Chongqing Haifu Medical Technology.

Biomedicine: Companies

China’s drug makers are speeding up – will AI be their secret weapon?

Chinese biotech firms are striking big global deals as drug makers, but could artificial intelligence take them to the next level?

United States

Chinese firms drawn to Brazil as they seek anchor for Latin America expansion

Chinese brands like Mixue, BYD, and Geely are surging into Brazil, leveraging strong trade ties and local strategies for growth.

Chinese ice cream and beverage chain Mixue opened its first Brazilian store in Sao Paulo, on April 11, 2026. Photo: Reuters
Mainland China

China’s tea-drink shops thirst for profits as price wars dry up prospects

‘I am learning a hard lesson of how involution can destroy my business,’ a Shanghai shop operator says.

Tea-drink sales grew 6.4 per cent in 2025, a sharp drop from annualised growth of more than 20 per cent over the past two decades. Photo: Shutterstock
Mainland China

Splashing out: how much would you expect to pay for LV’s latest quirky man bag?

Offbeat designs may not drive sales, but they sharpen brand identity and attract individuality-seeking buyers, analysts say.

Coffee

Chinese coffee brands need more than low prices to compete globally: analysts

Luckin, Lucky Cup, Cotti and Nowwa are expanding quickly overseas, but analysts warn success depends on consumer experience and quality.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement